The recall and guidance withdrawal are significant near-term headwinds, likely pressuring the stock. Monitor the Q1 2026 earnings call on May 4 for details on recall costs and liquidity. FDA approval timelines for original CGuard (Q3 2026) and TCAR (2H 2026) are key catalysts but face execution risk.
Price Chart
Executive Summary
InspireMD announced a voluntary U.S. recall of its CGuard Prime 135 cm delivery system due to subpar technical performance, while reporting strong global unit sales growth of 53% YoY in Q1 2026. The company withdrew its full-year 2026 revenue guidance and now expects FDA approval for its original CGuard delivery system in Q3 2026, with a TCAR indication potentially doubling the addressable market.
Key Facts
- Voluntary U.S. recall of CGuard Prime 135 cm delivery system initiated after controlled launch revealed subpar technical performance.
- Global year-over-year unit sales growth of 53% in Q1 2026; U.S. quarter-over-quarter unit sales growth of 34%.
- Full-year 2026 revenue guidance withdrawn due to temporary discontinuation of U.S. commercial activity.
- FDA approval for original CGuard delivery system anticipated in Q3 2026; CGuard Prime 80 cm for TCAR procedures expected in 2H 2026.
- TCAR indication could double addressable market (approx. 35,000 annual U.S. procedures).
- Design improvements to CGuard Prime delivery system expected FDA approval in 1H 2027.
- No safety implications for patients who have previously received the CGuard stent.
Financial Impact
Revenue guidance withdrawn; recall costs (refunds, inventory write-off, remediation) undisclosed; potential loss of U.S. sales until Q3 2026.
Risk Factors
- Recall costs and potential product liability lawsuits could strain liquidity.
- Delays in FDA approval for original CGuard or TCAR indication could extend U.S. revenue disruption.
- Going concern risk highlighted in forward-looking statements; may need dilutive capital raise.
- Competitive pressure from existing carotid stent systems during U.S. market absence.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286206 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 21, 2026 5w ago | 8-K | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Sep 21, 2026 5w ago | Press Release | $0.7500 $0.6895 | ▼ −8.07% | ▼ −7.05% | $0.4500 (−40.00%) |
Aug 17, 2026 10w ago | 8-K | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 17, 2026 10w ago | Press Release | $0.8798 $0.8699 | ▲ +1.13% | ▼ −0.07% | $0.4500 (+48.85%) |
Aug 10, 2026 11w ago | Press Release | $0.8500 $0.8816 | ▲ +3.72% | ▲ +4.12% | $0.4500 (−47.06%) |
Jul 29, 2026 12w ago | 8-K | $0.6718 $0.7222 | ▲ +7.50% | ▲ +3.88% | $0.4500 (−33.02%) |
Jul 23, 2026 13w ago | 8-K | $0.6835 $0.6718 | ▲ +1.71% | ▲ +2.09% | $0.4500 (+34.16%) |
Jul 2, 2026 16w ago | 8-K | $0.6990 $0.7121 | ▲ +1.87% | ▲ +0.94% | $0.4500 (−35.62%) |
May 21, 2026 22w ago | Insider Cluster | $1.00 $0.9900 | ▼ −1.00% | ▼ −2.66% | $0.4500 (−55.00%) |
May 15, 2026 23w ago | Insider Cluster | $1.05 $0.9500 | ▼ −9.52% | ▼ −11.14% | $0.4500 (−57.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers